Bioreductive drugs into the next millennium

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Oncogene·2020

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Blood cancer journal·2017

A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset.

Psychological medicine·2016

Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.

Clinical oncology (Royal College of Radiologists (Great Britain))·2014

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Oncogene·2013

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

British journal of cancer·2013

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Anti-cancer drug design·2002

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Anti-cancer drug design·2002

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

Anti-cancer drug design·2002

Photokilling of cultured tumour cells by the porphyrin derivative CF3.

Anti-cancer drug design·2002

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro.

Anti-cancer drug design·2002

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.

Anti-cancer drug design·2002

New-Onset Raynaud Phenomenon during Ropeginterferon Alfa-2b Therapy for Polycythemia Vera: A Case Report and Review of the Literature.

Case reports in oncology·2026

131I-labeled engineered hybrid cell membrane biomimetic nanocarrier targets gastric cancer and enhances radioimmunotherapy.

Materials today. Bio·2026

Plant-Derived Extracellular Vesicles Delivered by Microinfusion Microneedling for Androgenetic Alopecia: A Retrospective Case Series.

Skin appendage disorders·2026

Erratum: Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.

Blood neoplasia·2026

Machine learning driven precision medicine in tacrolimus dosing: current research and future perspectives in liver and kidney transplantation.

Frontiers in immunology·2026

Modular engineered outer membrane vesicles for synergistic cancer immunotherapy via PD-L1 blockade and epigenetic reprogramming.

Frontiers in immunology·2026

Related Experiment Videos

Bioreductive drugs into the next millennium

Related Concept Videos

Correction: A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset.

Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.

Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

Photokilling of cultured tumour cells by the porphyrin derivative CF3.

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro.

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.

New-Onset Raynaud Phenomenon during Ropeginterferon Alfa-2b Therapy for Polycythemia Vera: A Case Report and Review of the Literature.

131I-labeled engineered hybrid cell membrane biomimetic nanocarrier targets gastric cancer and enhances radioimmunotherapy.

Plant-Derived Extracellular Vesicles Delivered by Microinfusion Microneedling for Androgenetic Alopecia: A Retrospective Case Series.

Erratum: Brem EA, Shieh K, Juarez D, et al. A phase 1 study adding pitavastatin to venetoclax therapy in AML and CLL/SLL: a mechanism-based drug repurposing strategy. Blood Neoplasia. 2024;1(4):100036.

Machine learning driven precision medicine in tacrolimus dosing: current research and future perspectives in liver and kidney transplantation.

Modular engineered outer membrane vesicles for synergistic cancer immunotherapy via PD-L1 blockade and epigenetic reprogramming.

Related Experiment Videos

Bioreductive drugs into the next millennium

Related Concept Videos

Related Articles